An Early Phase 1 interventional study of Buprenorphine + naloxone (Suboxone) and Buprenorphine Injection in Opioid Use Disorder, sponsored by Rachel R. Luba. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by Rachel R. Luba · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies testing buprenorphine in Opioid-Related Disorders — 19 open to participants now, 21 under way, 5 of them phase 3. Buprenorphine · Opioid-Related Disorders.
Among the 173 studies testing buprenorphine in Opioid-Related Disorders, this one is the 54th largest by planned enrollment of the 172 interventional ones that give a count, is one of 7 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 17 of the 20 other live ones, and was the 164th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →19 of the 173 studies testing buprenorphine in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 19+
Pouya Azar · Sites in Canada
Ages 19+
Lifespan · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Men only
By country, each count listing its studies:
Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 66 · Phase 3 47 · Phase 4 41
First in 1988; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 19 across the 172 interventional studies. Of the 139 that completed or were terminated, 49 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 173 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Rachel R. Luba as lead sponsor.
Rachel R. Luba has 1 study filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
10 of the studies testing buprenorphine in Opioid-Related Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05011266Phase 3New York State Psychiatric InstituteEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder | 2027-01-01 |
| NCT06316830Phase 3Rhode Island HospitalIdentifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose | 2027-08-01 |
| NCT06494904Phase 3Yale UniversityStandard Versus High Dose ED-Initiated Buprenorphine Induction | 2027-09 |
| NCT06051890NYU Langone HealthAssessing Optimal XRB Initiation Points in Jail | 2026-12-01 |
| NCT04464980NYU Langone HealthOptimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 173 studies testing buprenorphine in Opioid-Related Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare buprenorphine formulations (sublingual buprenorphine versus long-acting injectable buprenorphine) for treating opioid use disorder among individuals who use fentanyl and/or other high potency synthetic opioids. Individuals aged 18-65 will be eligible for enrollment. The main questions it aims to answer are:
Are there differences in frequency of drug use after individuals start treatment with sublingual buprenorphine compared to injectable buprenorphine?
Are there differences in rates of sustained relapse after individuals start treatment with sublingual buprenorphine compared to injectable buprenorphine?
Investigators also seek to understand and explore:
How factors like body fat, body weight, and quantity of fentanyl use before treatment influence treatment outcomes.
How blood levels of buprenorphine and its metabolite norbuprenorphine early on in treatment may influence treatment outcomes.
How factors like craving and opioid withdrawal symptoms influence treatment outcomes.
Participants will:
Complete a brief overnight hospital stay in an inpatient research unit. This hospital stay will enable participants to start treatment with either sublingual buprenorphine or injectable buprenorphine.
Provide blood and urine samples while on the inpatient unit and at follow up.
Complete in-person follow up visits at 1-, 2-, 3- and 4-weeks after leaving the hospital to measure drug use, craving, withdrawal, quality of life, and physical health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Long-Acting Injectable Buprenorphine administered after participants receive and tolerate a single 4/1 mg sublingual buprenorphine/naloxone dose
Drug: Buprenorphine Injection
Titration onto sublingual buprenorphine/naloxone (standard of care)
Drug: Buprenorphine + naloxone (Suboxone)
Drug page: BuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care
Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose
Percentage of Days Abstinent from Opioids
Abstinence from Opioids (% days abstinent; continuous; longitudinal) during each week of the 4 week follow up period measured via the timeline follow back.
Time frame: 4 week follow up period
Sustained Relapse
Sustained relapse during the 4 week follow up period (binary), defined as 5 consecutive days of illicit opioid use reported on the timeline follow back at any point during the 4 week follow up period.
Time frame: 4 week follow up period
Time to Peak Clinical Opiate Withdrawal Scale (COWS) score
The time to peak Clinical Opiate Withdrawal Scale (COWS) score during the induction period (time-to-event/survival). The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.
Time frame: During the inpatient induction period (approximately 1 overnight stay)
Peak Clinical Opiate Withdrawal Scale (COWS) score
The peak Clinical Opiate Withdrawal Scale (COWS) score during the induction period (continuous). The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.
Time frame: During the inpatient induction period (approximately 1 overnight stay)
Dropout during induction
Dropout during the induction period (binary)
Time frame: During the inpatient induction period (approximately 1 overnight stay)
Exploratory Outcome 1: Craving
Craving as reported on the Opioid Craving Visual Analog Scale OC-VAS (longitudinal; continuous) during induction and follow up. The OC-VAS ranges from 0-100mm with higher ratings indicating more intense/severe craving.
Time frame: Induction Period (Overnight Inpatient Stay) and 4-week follow up period
Exploratory Outcome 2: Clinical Opiate Withdrawal Scale (COWS) Score
Opioid Withdrawal Symptoms as reported on the Clinical Opiate Withdrawal Scale (COWS; longitudinal; continuous) during induction and follow up. The COWS ranges from 0-48 with higher scores indicating more severe opioid withdrawal symptoms.
Time frame: Induction Period (Overnight Inpatient Stay) and 4-week follow up period
Exploratory Outcome 3: Time to first use of illicit opioids
Time to first use of illicit opioids during the 4-week follow up period (time-to-event/survival)
Time frame: 4-week follow up period
Plan to share: Yes — According to NIDA's policy for data management and sharing, de-identified data will be deposited into the NAHDAP repository.
Time frame: De-identified data will be made available no later than when the primary outcome paper is published or when the award ends. The data will be stored in the repository for at least 10 years after the funding period ends.
Access criteria: Once released to the repository, the investigator will not control data access.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 34 months after the start.
Of 55 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 34 months is above that.
Counting every sponsor, half of 79 studies reached it within 19 months; a quarter within 9 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Buprenorphine